Med BioGene reports pre-clinical results of its Diagnostic Lymphoma DNA Bioarray
Med BioGene Inc. announced the results of its pre-clinical studies involving its Diagnostic lymphoma Bioarray. The studies of fifty RNA samples derived from human lymphoma tissues suggest that MBI's Diagnostic Lymphoma Bioarray successfully differentiated between genes in both the diseased and healthy control samples.
Moreover, the results revealed a high dissimilarity between six lymphoma subtypes (Diffuse Large B-Cell, Mantle Cell, Follicular, Hodgkin, Marginal Zone and Small Lymphocytic) and the healthy control samples, indicating that the bioarray is able to detect differential expression profiles. The samples used in the studies did not include the subtype T-Cell Lymphoma; however, prior studies suggest that the bioarray is able to distinguish this subtype from healthy control samples. Sample replicates were also highly similar to one another, indicating a consistency in the bioarray.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.